Natera

The firm said it would likely do a joint submission of its ctDNA assay to the FDA and CMS for approval and a national coverage determination.

The molecular diagnostics firm recognized $62.3 million in first quarter 2018 revenues, and it processed more than 164,000 tests.

The company presented three posters at AACR, two of which demonstrated insights from its circulating DNA monitoring in colorectal and bladder cancers.

The suit alleges that Natera's Panorama test infringes US Patent No. 9,493,831 patent, which covers sequencing library preparation methods applied to maternal blood samples.

In Q4 Natera tallied revenues of $53.8 million compared to $49.3 million a year ago, falling short of the consensus Wall Street estimate of $57.1 million.

Natera and Qiagen have signed a 10-year agreement to develop cell-free DNA assays for use on Qiagen's GeneReader next-generation sequencing system.

The company agreed to settle a lawsuit alleging it improperly billed government health plans for its genetic tests.

The Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, and reversed the 3 percent loss it saw in December.

Natera outlined its work with pharmaceutical firms to use the Signatera assay, while Luminex was bullish about its growing molecular diagnostics business.

Natera said its liquid biopsy assay Signatera is well suited for the immuno-oncology field, particularly pharmaceutical companies developing personalized vaccines.

Pages

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.